-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Articles|April 28, 2023

Supplements and Featured Publications

  • Managed Care Considerations in the Management of CKD Associated With T2D

Managed Care Considerations in the Management of CKD Associated With T2D

This publication was paid for by and developed under the direction of Bayer. It was not peer reviewed. Financial support and promotional content direction were provided by members of Bayer Market Access team.

This AJMC® Clinical Brief describes ways in which payers can optimize management of patients with chronic kidney disease associated with type 2 diabetes.

Related to this article

Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.